Here are five key notes:
1. The iStent inject is approved by the Australian Therapeutics Goods Administration for use in conjunction with cataract surgery for the resection of intraocular pressure in adult patients with mild-to-moderate glaucoma currently treated with ocular hypotensive medication.
2. Numerous clinical studies show the implantation of stents with concomitant cataract surgery can help glaucoma patients achieve target IOP levels while significantly reducing their dependence on topical medications, which are often ineffective due to high rates of patient non-compliance.
3. The iStent inject stents are place directly into the eye’s drainage canal, restoring natural physiological fluid outflow in a straightforward procedure.
4. Frank Howes, MD, is an ophthalmic surgeon based in Brisbane, Australia and the first physician to implant the iStent inject.
5. Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma.
More articles on healthcare:
Nueterra divides into 2 companies: 4 highlights
15 statistics on physician investment mistakes
7 things to ASC leaders to know for Monday — Feb. 8, 2016
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.